TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Enhanced Continuity of Pharmacy Care for Cardiovascular or Pulmonary Diseases
Brief Summary: This study will test whether enhanced continuity of pharmacy care that includes increased communication between inpatient and outpatient settings will improve the appropriateness of medication therapy and reduce the number of serious adverse drug events, hospitalizations and unscheduled office visits in vulnerable patients with cardiovascular disease, pulmonary disease or diabetes.


Options:
A: Inclusion Criteria:

The Project Director will meet with the subject to determine if the patient meets inclusion or exclusion criteria.

Inclusion criteria include are patients who:

1. are over 18 years old;
2. are to be discharged to a community, non-institutionalized setting;
3. report that they desire to be hospitalized in the future if there is a clinical need; and
4. are admitted to Firm B of the BMC Inpatient Service.

Exclusion Criteria:

1. admitted to non-general Medical services at BMC (e.g., orthopedic surgery, obstetrics and gynecology, otolaryngology, general surgery, or psychiatry);
2. requiring hospice, nursing home or other institutional settings upon discharge,
3. who die during the admission,
4. subjects who speak languages other than English;
5. those who indicate that they have no access to a telephone or unable to give a contact telephone number; and
6. those not competent to sign informed consent.
B: Inclusion Criteria:

* 80 years and older
* Acute admission to study ward

Exclusion Criteria:

* \<80 years
* Scheduled admission
* Previously admitted to studyward during study period
C: Inclusion Criteria:

* Speaks either English or Spanish
* Willing to obtain all long-term prescriptions from one community pharmacy during the 90-day study period
* Diagnosed with at least one of the following conditions: high blood pressure, hyperlipidemia, heart failure, coronary artery disease, heart attack, stroke, transient ischemic attack, asthma, chronic obstructive pulmonary disease (COPD), diabetes, or receiving oral anticoagulation therapy
* Admitted to the general medicine, family medicine, cardiology, or orthopedics services hospital department

Exclusion Criteria:

* Does not have a working telephone
* Has a hearing impairment that does not allow the use of a telephone
* Enrolled in Iowa Care (i.e., individual has no community physician or community pharmacist following hospital discharge)
* Life expectancy estimated at less than 6 months at the time of study entry
* Dementia or cognitive impairment
* Severe psychiatric or psychosocial factors, including substance abuse, that may impair the desire or ability to complete all aspects of the study
* Admission to the psychiatric, surgery, or hematology/oncology services hospital department
D: Inclusion Criteria:

* Age 18 years or older
* Index hospitalization for congestive heart failure or chronic obstructive pulmonary disease
* Access to telephone

Exclusion Criteria:

* Cognitive impairment
* Resident of a nursing home
* Does not speak English

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effects of Zinc as an Adjunct to Treatment of Pneumonia in Young Children
Brief Summary: The propose of this study is to evaluate if zinc given as an adjunct to standard treatment of severe pneumonia in young children shortens the duration and reduces treatment failure, and if these effects are pathogen-dependant.


Options:
A: Inclusion Criteria:

4-6 months of age (stratified by HIV status) Infant able to take oral preparations Consent of parent/guardian HIV status obtained from mother and child

Exclusion Criteria:

Documented micronutrient supplementation other than vitamin A in the preceding month Less than 60% of mean weight for age by NCHS guidelines (micronutrient intervention obligatory according to WHO guidelines for management of severely malnourished children) Persistent diarrhea (\>=7 days) at the time of study enrollment Exclusive breastfeeding Infants in whom a second confirmatory HIV test cannot be obtained (when required) Co-enrollment of the infant in other clinical intervention trials e.g. antibiotic or vaccine trials
B: Inclusion Criteria:

1. Age between 12-59 months
2. Moderate malnutrition (61-75% Weight / Age - NCHS Median)
3. Duration of diarrhoea of 5 days
4. Culture confirmed shigella spp in stool on enrolment

Exclusion Criteria:

1. Measles infection in the past six months
2. Presence of obvious systemic illnesses
3. Severe malnutrition
4. Residence in a location requiring a journey of\>2 hour from the Dhaka Hospital of the ICDDR,B
5. Refusal to give consent
C: Inclusion Criteria:

* Children aged 2- 35 months with a history of cough (duration \<14days) and difficult breathing of \</= 72hours' duration, with lower chest indrawing.
* Availability of informed consent.

Exclusion Criteria:

* Children with severe wasting (\<70% NCHS median weight for height)
* Severe anemia (hemoglobin \<7 gm/dl.)
* Presence of heart disease with or without signs of cardiac failure.
* Child with a chronic cough (lasting for ≥14 days)
* Documented tuberculosis with ongoing treatment.
* Associated other severe diseases that require special care or surgical intervention.
* Children with concomitant diarrhea with some/severe dehydration
* Children with a history of recurrent wheezing
* Children enrolled in the study within the last 6 months of this visit
D: Inclusion Criteria:

* Children from 2 to 59 months of age with severe pneumonia admitted to the Children´s Hospital, whose parents are willing to provide written informed consent will be eligible for participation

Exclusion Criteria:

* Children suffering from marasmus or kwashiorkor, measles, pneumonia due to aspiration of a foreign body, hepatic or renal disease, sepsis, congenital abnormalities (cardiac, renal, or genetic), complicated pneumonia (lung abscess, pleural effusion, pneumatocele, atelectasis), or severe anemia (hemoglobin less than 8 g/dL \[this cut-off is based on clinical experience with severe anemia at high altitude\])
* Children whose parents refuse to provide written informed consent.

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program
Brief Summary: The objective of the trial is to assess the impact of a disinfection and hand hygiene program on absenteeism in elementary school classrooms. Students in intervention classrooms will use alcohol-based hand sanitizers at school, and their classrooms will be disinfected using quaternary ammonium wipes. We hypothesize that the use of disinfectants and hand hygiene products in elementary school classrooms will reduce absenteeism.


Options:
A: Inclusion Criteria:

* Member of a designated elementary school classroom in the Avon school system
B: Inclusion Criteria:

* Current or part-time student at McMaster University
* 17 year of age or older
* Currently living:

  i. In residence or, ii. Off-campus with at least one student housemate
* Willing and able to sign an informed consent

Exclusion Criteria:

* Students who do not meet the inclusion criteria
* Currently living at home with parents
* History or diagnosis of hypercalcemia
* Diagnosis of parathyroid disorder (hyper or hypo)
* Diagnosis of chronic kidney disease
* Use of anticonvulsants
* Malabsorption syndromes
* Diagnosis of sarcoidosis
* Currently pregnant or planning a pregnancy
* Inability to swallow capsules
C: Inclusion Criteria:

* influenza like illness symptoms
* positive rapid test for influenza
* inclusion within 48h of symptom onset
* inclusion of at least 3 members of a household (including index case)

Exclusion Criteria:

* severe illness
* other cases of similar symptoms within 14 days before onset of symptoms in index patient
* severe asthma or COPD
* pregnancy of index
D: Inclusion Criteria:

* Hand hygiene opportunities at the point of patient care

Exclusion Criteria:

* Hand hygiene opportunities not concerning patient care like personal hygiene

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Brief Intervention for Regular Prescription Drug Use and Prescription Drug Use Disorders in General Hospital
Brief Summary: In a randomized controlled trial, patients recruited in a general hospital and fulfilling criteria for regular consumption (more than 60 days within the last three months), dependence or abuse of prescription drugs will be randomly allocated to two conditions:(1) Intervention group consisting of two counselling sessions based on Motivational Interviewing plus a personalized feedback, (2) Control group receiving a booklet on health behavior.

Outcome assessment will be conducted after 12 months. The hypothesis is that counseling leads to greater reduction in consumption of prescription drugs (including discontinuation) and elevated readiness to change at follow-up.


Options:
A: Inclusion Criteria:

* within the specified age range
* \>= 1 past two month binge drinking episode
* right-handed
* proficient in English
* agree to be contacted for the 3, 6, and 12 month follow ups
* informed consent of a parent/guardian, if under 18 years old
* informed assent/consent of participating youth

Exclusion Criteria:

* \> 3 past-month instances of non-nicotine and/or non-cannabis substance use (e.g., methamphetamine)
* evidence of brain injury/illness or neurological disorder including psychosis
* lifetime loss of consciousness \>= 2 min
* unremovable metal on/in body, or other functional magnetic resonance imaging (fMRI) contraindications (e.g., pregnancy)
B: Inclusion Criteria:

* Prescription drug abuse
* Prescription drug dependence
* Regular prescription drug consumption (\>60 times/last three months)

Exclusion Criteria:

* Current treatment for substance abuse problems
* Terminal illness
C: Inclusion Criteria:

* First arrest for driving under the influence of alcohol
* Arrest involved operation of a motor vehicle
* At least 18 years of age
* English-speaking

Exclusion Criteria:

* Arrest involved injury to another person
D: Inclusion Criteria:

* Male or Female age 18 or older
* Serum antibody and polymerase chain reaction positive for hepatitis C
* Drinking greater than 7 drinks for each of the proceeding 2 weeks or one day heavy drinking day per week for 2 week (heavy drinking day:\>4 drinks in one day)
* Diagnosed with alcohol abuse or dependence

Exclusion Criteria:

* Diagnosis of cocaine, methamphetamine or opioid dependence within the past 6 months
* Unable to attend clinic appointments
* Any known pre-existing medical conditions that could interfere with participation in the protocol, such as: CNS trauma, known cognitive impairment, dementia, encephalopathy from liver disease, acute psychiatric instability, such as significant psychosis, mania, or elevated risk for suicide

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Brief Intervention for Regular Prescription Drug Use and Prescription Drug Use Disorders in General Hospital
Brief Summary: In a randomized controlled trial, patients recruited in a general hospital and fulfilling criteria for regular consumption (more than 60 days within the last three months), dependence or abuse of prescription drugs will be randomly allocated to two conditions:(1) Intervention group consisting of two counselling sessions based on Motivational Interviewing plus a personalized feedback, (2) Control group receiving a booklet on health behavior.

Outcome assessment will be conducted after 12 months. The hypothesis is that counseling leads to greater reduction in consumption of prescription drugs (including discontinuation) and elevated readiness to change at follow-up.


Options:
A: Inclusion Criteria:

* incarcerated women
* current hazardous drinking
* current HIV risk behavior

Exclusion Criteria:

-
B: Inclusion Criteria:

* adolescents (ages 14-18) presenting to the ED for a medical injury or illness (except exclusions as noted below)
* adolescents ability to provide informed assent/consent depending on age
* access to a parent or guardian to provide informed consent

Exclusion Criteria:

* adolescents who do not understand English
* prisoners
* adolescents classified by medical staff as "Level 1" trauma
* adolescents deemed unable to provide informed consent
* adolescents treated in the ED for suicide attempts
* adolescents triaged to the psychiatric ED
C: Inclusion Criteria:

* 18 years of age or older
* Fluent in English or Spanish
* Consume risky amounts of alcohol
* Provide 2 contacts to assist with follow-up
* Have no plans to move from the local area within a year of screening
* Score \>21 on Mini-Mental State Examination (no serious cognitive impairment)
D: Inclusion Criteria:

* Prescription drug abuse
* Prescription drug dependence
* Regular prescription drug consumption (\>60 times/last three months)

Exclusion Criteria:

* Current treatment for substance abuse problems
* Terminal illness

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomised Trial of Oral Nutritional Supplements Versus Dietary Advice on Clinical Nutrition in the Community.
Brief Summary: The purpose of this study is to determine the best form of dietary intervention to undernourished elderly individuals in care homes.

The research aims to test the null hypothesis that there is no difference between oral nutritional supplements and dietary advice as the first line treatment for malnutrition.


Options:
A: Inclusion Criteria:

* Nursing home residents with a chronic somatic disease and long term care

Exclusion Criteria:

* Residents were excluded when they were in a terminal phase of a disease, had total parenteral feeding or were not able to give informed consent due to their physical or mental condition.
B: Inclusion Criteria:

* old age home residents age 75 years or above, CDR\<1

Exclusion Criteria:

* tube fed residents
C: Inclusion Criteria:

Patients will be recruited in a consecutive prospective manner.

* emergency admissions to acute medical wards and
* ability to gain consent from patient or relatives

Exclusion Criteria:

* Patient acutely unwell or palliative care
* Patient lacking capacity to consent and no assent given by relatives
* Patients who are tube fed or nil-by-mouth
D: Inclusion Criteria:

* Male or female
* Age \> 50 years
* At risk of malnutrition
* Competent to provide written informed consent and to answer questions
* Able to eat and drink
* Willingness to take part in the trial and to follow the trial protocol

Exclusion Criteria:

* Requirement for tube or parenteral nutrition
* Galactosemia
* Receiving current oral nutritional supplementation
* Palliative care
* Chronic renal disease requiring dialysis
* Liver failure
* Malignancy
* Participation in other studies

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients With Advanced Tumours.
Brief Summary: To determine the safety, tolerability, dose-limiting toxicity (DLT), pharmacokinetic-pharmacodynamic profile, and maximum tolerated dose (MTD) of KU-0059436 when administered orally to patients with advanced solid tumours. To further evaluate the safety and efficacy of KU-0059436 in an expanded cohort of BCRA-enriched population, primarily ovarian cancer patients


Options:
A: Inclusion Criteria:

* Diagnosed with serous ovarian cancer
* Patients who have received no more than 3 previous platinum containing treatments and were progression free for at least 6 months following the end of the last platinum treatment
* At least one lesion that is suitable for accurate repeated measurements

Exclusion Criteria:

* Patients receiving any systemic anticancer chemotherapy, radiotherapy (except palliative) within two weeks from the last dose prior to study treatment
* Hypersensitivity to pre medications required for treatment with paclitaxel/carboplatin
B: Inclusion Criteria:

* Histologically confirmed high grade serous and/or undifferentiated carcinoma of ovary, fallopian tube or peritoneum
* Oestrogen, progesterone and HER2 negative advanced adenocarcinoma of the breast
* Known BRCA positive breast cancer or ovarian cancer, that is not high grade serous or undifferentiated tubo-ovarian carcinoma.
* Performance status of no more than 2.

Exclusion Criteria:

* Any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within 4 weeks prior to entry
* Major surgery with 4 weeks of entering the study and must have recovered from effects of any major surgery .
C: Inclusion Criteria:

* Advanced ovarian cancer with positive BRCA1 or BRCA2 status
* Progressive or recurrent disease after platinum-based chemotherapy
* Measurable disease by RECIST

Exclusion Criteria:

* Previous anthracycline treatment
* Brain metastases
* Less than 28 days since last treatment used to treat the disease
* Considered a poor medical risk due to a serious uncontrolled disorder
D: Inclusion Criteria:

* Confirmed malignant advanced solid tumour refractory to standard therapy or for which no suitable effective standard therapy exists.

Exclusion Criteria:

* Anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the 4 weeks prior to trial entry (or a longer period depending on the defined characteristics of the agents used).

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Single-Arm Open-Label Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous and/or Subcutaneous C.E.R.A for the Maintenance of Hemoglobin Levels in Dialysis Patients With Chronic Renal Anemia
Brief Summary: This single arm study will assess the efficacy and safety of Mircera when administered once monthly, subcutaneously or intravenously, for the maintenance of hemoglobin levels in dialysis patients with chronic renal anemia. Patients currently receiving maintenance treatment with epoetin alfa will receive monthly injections of Mircera with a starting dose (120, 200 or 360 micrograms) derived from the dose of epoetin alfa they were receiving in the week preceding study start. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Options:
A: Inclusion Criteria:

* chronic renal anemia;
* continuous iv maintenance epoetin alfa therapy, with the same dosing interval during the previous month to and during SVP;
* regular hemodialysis for greater than or equal to (\>=) 3 months

Exclusion Criteria:

* transfusion of red blood cells during previous 2 months
* poorly controlled hypertension requiring interruption of epoetin alfa treatment in previous 6 months;
B: Inclusion Criteria:

* regular long term hemodialysis with same schedule for greater than or equal to (\>=) 12 weeks
* continuous IV or SC maintenance epoetin beta or darbepoetin alfa therapy, with the same dosing interval during the previous month, and no change in total weekly dose

Exclusion Criteria:

* transfusion of red blood cells during previous 2 months
* significant acute or chronic bleeding
* poorly controlled hypertension requiring hospitalization or interruption of epoetin beta/darbepoetin alfa treatment in previous 6 months
* weekly dose of epoetin beta greater than (\>) 16000 international units (IU), or weekly dose of darbepoetin alfa \>80 micrograms during previous month
C: Inclusion Criteria:

* adult patients, \>=18 years of age;
* chronic renal anemia;
* hemodialysis or peritoneal dialysis, with same mode of dialysis for \>=3 months before and throughout screening period;
* stable maintenance epoetin alfa therapy for past 2 months.

Exclusion Criteria:

* transfusion of red blood cells during previous 2 months;
* poorly controlled hypertension requiring interruption of epoetin alfa in past 6 months;
* acute or chronic bleeding during previous 2 months.
D: Inclusion Criteria:

* adult patients \>=18 years of age;
* chronic renal anemia;
* on dialysis therapy for at least 12 weeks before screening;
* receiving darbepoetin alfa iv for at least 8 weeks before screening.

Exclusion Criteria:

* women who are pregnant, breastfeeding or using unreliable birth control methods;
* administration of another investigational drug within 4 weeks before screening, or during the study period.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Impact and Safety of a Physical Training Program on Health-related Quality of Life in Patients With Cirrhosis and Portal Hypertension
Brief Summary: Physical training improves quality of life (QOL) in non-hepatic diseases. It is possible that the same effect happens in patients with cirrhosis and portal hypertension. Hepatic encephalopathy may also benefit from physical activity by increasing ammonia metabolism. The intention of this study is to assess if patients can improve their QOL and hepatic encephalopathy during a physical training program, and to address its safety.


Options:
A: Inclusion Criteria:

- Age \>18 and less than or equal to 70 years Liver Cirrhosis Child Pugh Class A or B If required, primary or secondary Variceal prophylaxis in place

Exclusion Criteria:

- Post-liver transplantation Hepatocellular carcinoma beyond transplant criteria Active non-hepatocellular carcinoma malignancy Significant cardiac disease Hemoglobin (\<80 g/L) Oxygen saturation at rest \<95% Known myopathy Chronic renal failure on dialysis Physical impairment making it impossible to ride an exercise bike or treadmill Orthopedic abnormality preventing exercise training HIV infection Patient unwilling to consent to study Child Pugh class C
B: Inclusion Criteria:

* compensated liver cirrhosis.

Exclusion Criteria:

* hepatocellular carcinoma,
* active alcoholism (less than 1 year),
* decompensated cirrhosis,
* variceal bleeding less than 3 months,
* contraindication for exercise.
C: Inclusion Criteria:

* Biopsy-proven or clinically evident cirrhosis
* Able to perform exercise

Exclusion Criteria:

* Overt hepatic encephalopathy grades 3 or 4
* Cardiovascular complications (pulmonary hypertension, heart failure)
* Diabetes mellitus and microangiopathic complications, or under treatment with insulin
* Renal failure
* Portal hypertension with high risk for variceal bleeding
* Hepatocellular carcinoma
D: Inclusion Criteria:

* Patients ≥40 years of age with COPD in GOLD stage II to IV (postbronchodilator FEV1/FVC≤0.70, postbronchodilator FEV1≤80% predicted) are eligible if in- or outpatient treatment of their last exacerbation ended ≥4 weeks ago.

Exclusion Criteria:

* Patients who received mechanical ventilation in the previous 12 months (because of extremely poor prognosis), patients with co-morbidities associated with a life expectancy of ≤12 months, patients diagnosed with dementia, psychosis or other psychiatric illness that invalidate assessment of patient-reported parameters and patients who cannot complete thr baseline assessment due to language difficulties.

Answer: C